When I was a global product manager in big pharma, my US counterpart mentioned to me one day that “we do generics properly in the US, not like you do in Europe.” He meant that when a small molecule went generic in the US, and the 180-day first-to-file exclusivity expired, the former branded price was massacred. It was true, in the first year SmithKline’s Tagamet went generic, they lost 80% of sales. Why then does the same not happen for biosimilars, which are meant to be the generic equivalents of small molecule drugs after loss of exclusivity. Send us a text Suggestion box (Suggestions on future episodes, points for clarification, comments, etc.) Subscribe (Get notified when new episodes are available. NO marketing!) Disclaimer Ready to create your own impactful podcast series? Contact us at elearningbytes.co.uk to get started!

Ver todos los episodios